


## TRV-120027 TFA

<b>Cat. No.:</b>	HY-P2141A
<b>Molecular Formula:</b>	C <sub>45</sub> H <sub>68</sub> F <sub>3</sub> N <sub>13</sub> O <sub>12</sub>
<b>Molecular Weight:</b>	1040.1
<b>Sequence:</b>	{Sar}-Arg-Val-Tyr-Ile-His-Pro-Ala
<b>Sequence Shortening:</b>	{Sar}-RVIIHPA
<b>Target:</b>	Angiotensin Receptor; Arrestin
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Sealed storage, away from moisture and light
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (96.14 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		0.9614 mL	4.8072 mL	9.6145 mL
<b>5 mM</b>			0.1923 mL	0.9614 mL	1.9229 mL	
	<b>10 mM</b>		0.0961 mL	0.4807 mL	0.9614 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (2.40 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.40 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (2.40 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling<sup>[1]</sup>. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment<sup>[2]</sup>.</p>
--------------------	--

<b>IC<sub>50</sub> &amp; Target</b>	IC50: the angiotensin II receptor type 1 (AT1R) <sup>[1]</sup>								
<b>In Vitro</b>	<p>TRV120027 TFA (100 nM) significantly increases the AT1R and TRPC3 association with the immunoprecipitated β-arrestin-1 in HEK293 cells co-transfected with Flag-AT1R-cherry, HA-β-arrestin-1 and TRPC3-GFP<sup>[2]</sup>.</p> <p>TRV120027 TFA (100 nM) induces an [Ca<sup>2+</sup>]<sub>i</sub> increase in HEK293 cells co-transfected with AT1R, β-arrestin-1, and TRPC3, which are significantly blocked by Pyr3 pre-incubation in HEK293 cells co-transfected with Flag-AT1R-Cherry, HA-β-arrestin-1, and TRPC3-GFP<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<b>In Vivo</b>	<p>TRV120027 TFA (intravenous injection; 0.3 or 1.5 μg/kg per minute; infusion rate, 0.5 mL/min) when added to furosemide decreases cardiac preload and afterload, systemic and renal vascular resistances, and left ventricular external work while increasing cardiac output and renal blood flow. GFR and renal excretory function are maintained in canines with experimental HF<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male mongrel dogs (weight, 20.5–30 kg)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.3 or 1.5 μg/kg per minute; infusion rate, 0.5 mL/min</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection</td> </tr> <tr> <td>Result:</td> <td>Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.</td> </tr> </table>	Animal Model:	Male mongrel dogs (weight, 20.5–30 kg) <sup>[1]</sup>	Dosage:	0.3 or 1.5 μg/kg per minute; infusion rate, 0.5 mL/min	Administration:	Intravenous injection	Result:	Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.
Animal Model:	Male mongrel dogs (weight, 20.5–30 kg) <sup>[1]</sup>								
Dosage:	0.3 or 1.5 μg/kg per minute; infusion rate, 0.5 mL/min								
Administration:	Intravenous injection								
Result:	Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.								

## CUSTOMER VALIDATION

- J Am Heart Assoc. 2022 Feb 15;11(4):e022070.
- Eur J Pharmacol. 2023 May 18;175780.
- University of Medicine Berlin. 2023 Mar.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Boerrigter G, et al. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. *Circ Heart Fail*. 2012 Sep 1;5(5):627-34. Epub 2012 Aug 13.

[2]. Liu CH, et al. Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling. *Nat Commun*. 2017 Feb 9;8:14335.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA